The Fas/Fas-ligand system: A mechanism for immune evasion in human breast carcinomas

Breast Cancer Research and Treatment

Volumn 54, Issue 3, 1999, Pages 245-253

  Gutierrez, Linda S ^a   Eliza, Mariel ^a   Niven Fairchild, Tracy ^a   Naftolin, Frederick ^a   Mor, Gil ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Breast carcinoma; Immunology; Tolerance suppression; Tumor immunology

Indexed keywords

CD3 ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ADIPOSE TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD VESSEL; BREAST CARCINOMA; CANCER CELL; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOPLASM; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE; LYMPHOCYTIC INFILTRATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING;

EID: 0033061705     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006102601215     Document Type: Article

References (26)

1. 1. Bergelson L: Gangliosides and antitumor immunity. Clin Invest 71: 590, 1993
2. 2. Yagita M, Seppo A, Renkonen O, Saksela E: Deacetylase activity of human tumor cells producing immunosuppressive aminosugars: Its possible role in resistance to cell mediated cytotoxicity. Cancer Res 53: 5600, 1993
3. 3. O'Mahony A, O'Sullivan G, O'Connell T, Cotter T, Collins J: An immune suppressive factor derived from esophageal squamous carcinoma induces apoptosis in normal and transformed cells of lymphoid lineage. J Immunol 151: 4847-49, 1993
4. 4. Lewis C: Cytokines in Neoplasia. Oxford University Press, Oxford, UK, 1992
5. 5. Griffith T, Brunner T, Fletcher S, Gree D, Ferguson T: Fas ligand induces apoptosis as a mechanism of immune privilege. Science 270: 1187-1192, 1995
6. 6. Bellgrau D, Gold D, Selawry H, Moore J, Franzusoff A, Duke R: A role for CD95 ligand in preventing graft rejection. Science 377: 630-632, 1995
7. 7. Bamberger A, Schulte H, Thuneke I, Erdmann I, Bamberger C, Asa S: Expression of the apoptosis-inducing Fas-ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. J Clin Endoc Metab 82: 3173-3175, 1997
8. 8. Mor G, Gutierrez L, Eliza M, Kahyaoglu F, Arici A: Fas/Fas ligand system induced apoptosis in human placenta and gestational trophoblastic disease. AJRI 40: 89-95, 1998
9. 9. Gutierrez L, Mor G, Eliza M, Arici A: Fas ligand expression and apoptosis in gestational trophoblastic disease: A model of immune tolerance. Lab Invest 78: 1, 1998
10. 10. Gutierrez L, Jansen A, Mor G: Fas ligand expression in normal, hyperplastic and neoplastic prostate. Mod Pathol 78: 601, 1998
11. 11. O'Connell J, O'Sullivan G, Collins J, Shanahan F: The Fas counter attack: Fas mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 184: 1075-1082, 1996
12. 12. Watanabe-Fukunaga R, Brannan C, Itoh N, Yonchara S, Copeland N, Jenkins N, Nagata S: The cDNA structure, expression and chromosomal assignment of the mouse Fas antigen. J Immunol 148: 1274, 1992
13. 13. Kondo T, Suda T, Fukuyama H, Adachi M, Nagata S: Essential roles of the Fas ligand in the development of hepatitis. Nature Med 3: 409-413, 1997
14. 14. Nagata S, Golstein P: The Fas death factor. Science 267: 1449-1456, 1995
15. 15. Strand S, Hofmann W, Hug H, Muller M, Otto G, Strand D, Mariani S, Stremmel W, Krammer P, Galle P: Lymphocyte apoptosis induced by CD95 (APO-1 Fas) ligand-expressing tumor cells - A mechanism of immune evasion? Nature Med 2: 1361-1366, 1996
16. 16. Sandhu G, Precup J, Kline B: Rapid one step characterization of recombinant vectors by direct analysis of transformed E. coli colonies. Bio Tech 7: 689, 1989
17. 17. Takahashi Y, Tanaka M, Inazawa J, Abe T, Suda T, Nagata S: Human Fas ligand: Gene structure, chromosomal location and species specificity. Int Immunol 6: 1567-1574, 1994
18. 18. Gabathuler R, Reid G, Kolaitis G, Driscoll J, Jefferies W: Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing. J Exp Med 180: 1415-1420, 1994
19. 19. Lebel M, Bertrand M, Mes-Masson A: Decreased Fas antigen receptor expression in testicular tumor cell lines derived from polyomavirus large T-antigen transgenic mice. Oncogene 12: 1127, 1996
20. 20. Ferguson T, Griffith T: A vision of cell death-insights into immune privilege. Immunol Rev 156: 167-184, 1997
21. 21. Aoe T, Okamoto Y, Saito T: Activated macrophages induce structural abnormalities of the T cell receptor-CD3 complex. J Exp Med 181: 1881-1886, 1995
22. 22. Nicolini A, Ferrari P, Spinelli R, Carpi A, Sagripanti A, Ambrogi F: Cell mediated immunity in breast cancer patients. Biomed Pharmacother 50: 337-343, 1996
23. 23. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L: The origin and function of tumour associated macrophages. Immunol Today 13: 265-270, 1992
24. 24. Alderson M, Tough T, Davis-Smith T, Braddy S, Falk B, Schooley K, Goodwin R, Smith C, Ramsdell F, Lynch D: Fas ligand mediates activation-induced cell death in human lymphocytes. J Exp Med 181: 71-77, 1995
25. 25. Mor G, Wei Y, Santen R, Gutierrez L, Eliza M, Lev B, Harada N, Wang J, Lysiak J, Diano S, Naftolin F: Macrophages, estrogen and the microenvironment of breast cancer. J Steroid Biochem Mol Biol 67: 404-411, 1998
26. 26. Arteaga C, Hurd S, Winnien A, Johnson M, Fendly B, Forbes T: Anti-Transforming Growth Factor (TGF-β) antibodies inhibit rat cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. J Clin Invest 92: 2569-2576, 1993